Please ensure Javascript is enabled for purposes of website accessibility

Perrigo Company PLC Had an Abominable April, and May Isn't Looking Any Merrier

By Sean Williams - May 9, 2016 at 11:44AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Perrigo has a generic pricing problem, and it's unlikely to be resolved anytime soon.

Image source: Perrigo. 

What: Shares of Perrigo (PRGO 1.11%), an over-the-counter and generic specialty pharmaceutical company, tumbled 24% in April, according to data from S&P Global Market Intelligence. The culprit can be traced to a press release on April 25, which updated Perrigo's first-quarter results and full-year guidance and announced the resignation of its long-tenured CEO.

So what: The big news was the announcement that CEO Joseph Papa, who led Perrigo for 10 years and transformed it into the over-the-counter juggernaut that it is today, resigned in favor of taking the CEO role at Valeant Pharmaceuticals. Papa leaving is certainly not what investors expected, especially with Perrigo coming so far off its recent highs. The concern with any CEO change is that a company's strategy can take an unexpected turn with a new individual in charge. If there is some solace here, it's that Perrigo decided to appoint from within, choosing its former president, John Hendrickson, as its new CEO.

Image source: Perrigo.

The other clobbering came from Perrigo's preliminary Q1 results and full-year guidance. Perrigo guided net sales to between $1.33 billion and $1.35 billion, and anticipates adjusted EPS of $1.71-$1.77. Comparatively, Wall Street's consensus had called for EPS of $1.89. Furthermore, its full-year adjusted EPS guidance of $8.20-$8.60 is another sharp cut from its prior forecast of $9.50-$9.80 in full-year EPS. Perrigo primarily blamed pricing pressures in its prescription segment and overall competitive pressure within the sector for the reduced forecast. 

Now what: It was an awful month to be a Perrigo shareholder, and, unfortunately, it doesn't look like May will offer any refuge. Growing competition in Perrigo's generic drug business has weighed on pricing, and will likely continue to do so in the coming quarters. At the same time, as reported by Bloomberg, Perrigo's shrinking margins could precipitate Standard & Poor's to cut its credit rating even further, after already having cut it in April to BBB-, the lowest investment grade level.

Adding more fuel to the fire, specialty pharmaceutical company Endo Pharmaceuticals (ENDP 22.42%) drastically cut its guidance last week, falling well short of Wall Street's expectations. Endo's cautionary tale on generic pricing and margins suggests that this is an industrywide phenomenon and not just something specific to Perrigo.

For the time being, I would suggest monitoring Perrigo from the sidelines. As a large OTC and generics company, it certainly could benefit from increased demand and prescriptions over the long run. But this bump in the road could extend many quarters out.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Perrigo Company plc Stock Quote
Perrigo Company plc
$41.02 (1.11%) $0.45
Endo International plc Stock Quote
Endo International plc
$0.57 (22.42%) $0.10

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 07/04/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.